Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034915.xml
Onkologische Welt 2018; 09(04): 195-196
DOI: 10.1055/s-0038-1670957
DOI: 10.1055/s-0038-1670957
Spektrum Onkologie
Prädiktive Biomarker für die Patientenselektion
ImmunonkologieFurther Information
Publication History
Publication Date:
10 September 2018 (online)
Zusammenfassung
Das adaptive Immunsystem gilt heute als „ideale“ Antitumortherapie, da mit T-Zellen und Antikörpern eine hohe Diversität gegeben ist, das Immunsystem kleinste chemische Alterationen unterscheidet und nach einem effektiven Antigen-Priming eine nachhaltige Wirkung erzielt wird. T-Zellen sind ideale Tumorkiller, sagte Prof. Andrea Tannapfel, Bochum, auf dem DKK in einer Keynote-Lecture.
#
#
-
Literatur
- 1 Chen DS. et al. Molecular pathways: Next-generation immunotherapy inhibiting programmed death-ligand 1 and programmed death-1.. Clin Cancer Res 2012; 18: 6580-6587
- 2 Callea M. et al. Differential expressoin of PD-L1 between primary and metastatic sites in clear cell renal cell carcinoma.. Cancer Immunol Res 2015; 3: 1158-1164
- 3 Alexandrov LB. et al. Signatures of mutional processes in human cancer.. Nature 2013; 500: 415-421
- 4 George TJ. et al. Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer. ASCO. 2016. Abstract 3587
-
Literatur
- 1 Chen DS. et al. Molecular pathways: Next-generation immunotherapy inhibiting programmed death-ligand 1 and programmed death-1.. Clin Cancer Res 2012; 18: 6580-6587
- 2 Callea M. et al. Differential expressoin of PD-L1 between primary and metastatic sites in clear cell renal cell carcinoma.. Cancer Immunol Res 2015; 3: 1158-1164
- 3 Alexandrov LB. et al. Signatures of mutional processes in human cancer.. Nature 2013; 500: 415-421
- 4 George TJ. et al. Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer. ASCO. 2016. Abstract 3587